Table 2.
Medication history at baseline and medication use during the index hospitalization
| Measures | Aerobika OPEP device users (N = 144) | IS users (N = 144) | p valuea |
|---|---|---|---|
| Use of medications | |||
| Antibiotics | 138 (95.8%) | 136 (94.4%) | 0.593 |
| Anticoagulantsb | 120 (83.3%) | 126 (87.5%) | 0.317 |
| Proton pump inhibitors | 15 (10.4%) | 20 (13.9%) | 0.353 |
| Medications for pulmonary hypertension | 0 (0%) | 0 (0%) | |
| Medications for pulmonary fibrosis | 0 (0%) | 0 (0%) | |
| Medications for respiratory diseases | |||
| Long-acting β2-agonists (LABA) | 0 (0%) | 1 (0.7%) | |
| Long-acting muscarinic antagonists (LAMA) | 0 (0%) | 1 (0.7%) | |
| LAMA/LABA combination | 0 (0%) | 0 (0%) | |
| Short-acting β2-agonists (SABA) | 69 (47.9%) | 65 (45.1%) | 0.612 |
| Short-acting muscarinic antagonists (SAMA) | 1 (0.7%) | 4 (2.8%) | 0.180 |
| Inhaled corticosteroids (ICS) | 1 (0.7%) | 6 (4.2%) | 0.059 |
| Oral corticosteroids (OCS) | 14 (9.7%) | 24 (16.7%) | 0.096 |
| ICS/LABA combination | 20 (13.9%) | 21 (14.6%) | 0.866 |
| SABA/SAMA combination | 58 (40.3%) | 60 (41.7%) | 0.800 |
| Theophylline | 0 (0%) | 4 (2.8%) | |
| Phosphodiesterase type 4 inhibitors | 0 (0%) | 0 (0%) | |
| Respiratory monoclonal antibodies | 0 (0%) | 0 (0%) | |
| Anti-inflammatory drugs | 0 (0%) | 0 (0%) | |
Values in table are presented as a number (of patients) with the percentage in parenthesis
aNonparametric Wilcoxon signed-rank test and nonparametric McNemar/Bowker test were used to assess the measures of Aerobika OPEP device vs. IS users
bCounts for anticoagulants other than warfarin: one Aerobika OPEP device patient and 11 IS patients had evidence of warfarin use